Uric Acid as a Risk Factor for Cardiovascular Diseases

Recently, hyperuricemia and its association with cardiovascular disease have been receiving more and more attention. The article talks about the role of uric acid in the body, the reasons for its increase and the impact of elevated uric acid levels on the cardiovascular system. The mechanisms of influence of hyperuricemia on the development and progression of cardiovascular diseases are presented. Medicinal and non-drug ways to reduce the level of uric acid in the blood are considered. From non-drug methods, attention is focused on the hypopurine diet, adequate drinking regimen and normalization of body weight. Separately, the effect on the level of uric acid of various drugs used in clinical practice is considered. In the light of current clinical guidelines, the issue of the need to prescribe drug therapy for asymptomatic hyperuricemia is discussed

The effect of non-specific LTD on pattern recognition in cerebellar Purkinje cells

© 2010 Safaryan et al; licensee BioMed Central Ltd.Poster presented at CNS 2010Peer reviewe

THE INFLUENCE OF HYDROGEN ALLOYING ON THE STRUCTURE, PHASE COMPOSITION AND TECHNOLOGICAL PLASTICITY OF THE TITANIUM ALLOY WITH ALUMINUM CONTENT EXCEEDING LIMIT SOLUBILITYABSTRACT

Установлено влияние водорода на структуру, фазовый состав и сопротивление горячей пластической деформации опытного сплава Ti–8,7Al–1,5Zr–2Mo, перспективного для изготовления силовых режущих хирургических инструментов. Установлено, что легирование водородом до 0,3 и 0,6 масс. % увеличивает объемную долю β-фазы при температурах α+α2+β-области и снижает предел текучести сплава на 115–200 МПа при температурах деформации 800–850С.The influence of hydrogen on the structure, phase composition and resistance of hot plastic deformation of the Ti–8.7Al–1.5Zr–2Moexperimental alloy, promising for the manufacture of power cutting surgical instruments, is established. It was found that doping with hydrogen to 0.3 and 0.6 wt. % increases the volume fraction of the β-phase at temperatures α+α2+β-region and reduces the yield strength of the alloy by 115–200 MPa at deformation temperatures of 800–850°C

LIPID-LOWERING THERAPY IN OUTPATIENT PRACTICE (ACCORDING TO THE ARGO-2 STUDY)

Aim. To study the features of lipid-lowering therapy with rosuvastatin in high and very high cardiovascular risk patients in real outpatient practice.Material and methods. Patients ≥30 years, visited internists or cardiologists of district outpatient clinics in the period from October 2013 to July 2014 were included into the study. Each patient fill in questionnaire. Determination of total cholesterol (TC) level was performed without special preparation of the patient using a portable photometric blood analyzer. Doctors prescribed rosuvastatin therapy when indicated, in accordance with the Guidelines, choosing the dose on their own. Repeated TC level was determined after 1 month.Results. TC level was initially determined in 10547 patients. Rosuvastatin treatment was recommended for all patients. Repeated TC level determination was performed in 7897 patients in an average after 33 days. Baseline TC level in them was 6.37±0.89 mmol/l, and after 1 month while taking rosuvastatin – 4.89±0.81 mmol/l (p<0.001). The change of TC level was -22% (p<0.001). The average prescribed dose of rosuvastatin was 11.88±5.1 mg per day. The most often (62.8%) rosuvastatin was prescribed in a dose of 10 mg per day, in 27.3% of patients – 20 mg per day, in 9.2% – 5 mg per day, and only 0.5% of patients took it in the maximal dose.Conclusion. In real clinical practice, rosuvastatin for treatment of patients with high or very high cardiovascular risk is often prescribed in moderate doses and rarely in the maximum dose despite the proven lipid-lowering effect

26th Annual Computational Neuroscience Meeting (CNS*2017): Part 3 - Meeting Abstracts - Antwerp, Belgium. 15–20 July 2017

This work was produced as part of the activities of FAPESP Research,\ud Disseminations and Innovation Center for Neuromathematics (grant\ud 2013/07699-0, S. Paulo Research Foundation). NLK is supported by a\ud FAPESP postdoctoral fellowship (grant 2016/03855-5). ACR is partially\ud supported by a CNPq fellowship (grant 306251/2014-0)

THE CAPABILITIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CLINICAL PRACTICE: FOCUS ON VASOPROTECTION

Data of large-scale research that shows comprehensive abilities of an angiotensin converting enzyme (ACE) inhibitors in clinical practice were represented. The traditional usage of ACE inhibitors in patients with arterial hypertension and chronic heart failure has extended recently. The study results demonstrate the efficacy of ACE inhibitors in slowing down of disease progression related to atherosclerosis and prove the possibility of a new clinical approach. Evidences support new strategic abilities of a number of ACE inhibitors (ramipril, perindopril), which are associated with vasoprotection.</p

New potential of ACE inhibitors in clinical practice

The paper reviews the results of the studies demonstrating new potential of ACE inhibitors. The traditional clinical niche for ACE inhibitor therapy (arterial hypertension, heart failure, diabetic nephropathy) has been extended recently. Substantial vasoprotective effect of these medications has an important role in decelerating progression of atherosclerotic cardiovascular pathology. In addition, a differential assessment of protective effects, together with prognosis improvement among high-risk patients, is presented for various ACE inhibitors